|
CME Information Page
January 6, 2009–eJournal Club Session
Release Date: January 6, 2009
Expiration Date: January 6, 2010
Term of Offering
This activity has a release date of January 6, 2009, and is valid until January 6, 2010. Requests for credit must be received no later than January 6, 2010. This CME activity was planned and produced in accordance with ACCME Essential Areas and Policies. Please refer to the posttest at the end of this activity for further instruction regarding credit.
On completion of the program, please electronically submit the posttest and evaluation for processing. A score of at least 70% is required for credit to be awarded. A certificate of credit will be returned to you within 4–6 weeks. The forms must reach DIME by January 6, 2010. If you have any questions, email DIMEinfo@DIMedEd.org.
Article Title: Clopidogrel Use and Bleeding After Coronary Artery Bypass Graft Surgery
Activity Purpose
To evaluate the impact of clopidorgel use on bleeding after coronary artery bypass graft (CABG) surgery and to recognize other determinants of bleeding in this context.
Statement of Need/Program Overview
This program intends to broaden the reach of atherothrombosis prevention and treatment protocols by providing a review of the current literature by today’s foremost experts.
Learning Objectives
On completion of this activity, participants should be able to:
- Identify the determinants of bleeding in relation to CABG and the baseline characteristics of patients who are more prone to bleed
- Assess the impact of clopidogrel use in patients who are undergoing elective or urgent CABG
- Select appropriate strategies to address CABG related bleeding due to various causes
Target Audience
This activity is targeted to physicians with an interest in atherothrombosis.
Sponsored by the Discovery Institute of Medical Education
www.DIMedEd.org
Funding Statement
This activity is funded through an educational grant from the Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership.
Faculty/Editorial Board
Editor-in-Chief:
Christopher P. Cannon, MD
Associate Professor of Medicine
Harvard Medical School
Senior Investigator, TIMI Study Group
Cardiovascular Division
Brigham and Women’s Hospital
Boston, Massachusetts
Discussant
Christopher B. Granger, MD
Associate Professor
Department of Medicine
Division of Cardiology
Co-Director, Clinical Trials
Duke Clinical Research Institute
Durham, North Carolina
Accreditation Statement
DIME is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation Statement
DIME designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Disclosures
DIME requires that all persons who were in a position to control or influence the content of this CME activity disclose all relevant financial relationships with any commercial interest. This information is used to: (1) determine whether a conflict exists, (2) resolve the conflict by initiating a content validation process, and (3) advise learners of this information.
Christopher P. Cannon, MD
Sources of Funding for Research: Accumetrics; AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership; GlaxoSmithKline; Merck & Co., Inc.; Merck/Schering-Plough Pharmaceuticals Partnership; Schering-Plough Corporation
Consulting Agreements: None
Speakers’ Bureau/Honorarium Agreements: None
Financial Interests/Stock Ownership: None
Discussion of Off-label, Investigational, or Experimental Drug Use: None
Christopher B. Granger, MD
Sources of Funding for Research: AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; deCODE genetics Inc.; Genentech, Inc.; GlaxoSmithKline; Novartis Pharmaceuticals Corp; sanofi-aventis Group; The Medicines Company
Consulting Agreements/Advisory Board Membership: AstraZeneca Pharmaceuticals LP; Genentech, Inc.; GlaxoSmithKline; INO Therapeutics; Lilly ICOS; Novartis Pharmaceuticals Corp; sanofi-aventis Group; Takeda Pharmaceutical Company Limited; The Medicines Company
Speakers’ Bureau/Honorarium Agreements: AstraZeneca Pharmaceuticals LP; GlaxoSmithKline; INO Therapeutics; Lilly ICOS; Novartis Pharmaceuticals Corp; sanofi-aventis Group; The Medicines Company
Financial Interests/Stock Ownership: None
Discussion of Off-label, Investigational, or Experimental Drug Use: None
Inquiries
All inquiries should be directed to:
DIME
222 Merchandise Mart Plaza, Ste 4-160
Chicago, IL 60654
DIMEinfo@DIMedEd.org
©2009 DIME
| 
